Preserved in Portico This version is not peer-reviewed
Development of In Vitro Corneal Models: Opportunity for Pharmacological Testing and Legislative Aspects
: Received: 29 September 2020 / Approved: 30 September 2020 / Online: 30 September 2020 (15:04:49 CEST)
: Received: 24 October 2020 / Approved: 26 October 2020 / Online: 26 October 2020 (11:45:00 CET)
A peer-reviewed article of this Preprint also exists.
Journal reference: Methods Protoc 2020, 3, 74
Human eye is a specialized organ with complex anatomy and physiology, because it is characterized by different cell types with specific physiological functions. Given the complexity of the eye, ocular tissues are finely organized and orchestrated. In the last few years many in vitro models have been developed, in order to meet the 3Rs principle (Replacement, Reduction and Refinement) for eye toxicity testing which is necessary to ensure that the risks associated with ophthalmic products meet appropriate safety criteria and are clearly labelled. In vitro preclinical testing is now a well-established practice of significant importance for evaluating the efficacy and safety of cosmetic, pharmaceutical, and nutraceutical products. Along with in vitro testing, also computational procedures, herein described, for evaluating the pharmacological profile of potential ocular drug candidates including their toxicity, are in rapid expansion. In this review the ocular cell types and functionality are described providing an overview about the scientific challenge for the development of three-dimensional in vitro models.
3D in vitro models; eye research; in silico analysis; eye anatomy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.